 PALO ALTO, Calif., Dec. 04, 2020 GLOBE NEWSWIRE -- BridgeBio Pharma, Inc. Nasdaq: BBIO, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on December 1, 2020, the compensation committee of BridgeBios board of directors granted 15 new employees options to purchase an aggregate of 15,351 shares of the Companys common stock with a per share exercise price of 51.13 and restricted stock units for an aggregate of 21,092 shares of the Companys common stock. All of the above-described awards were made under BridgeBios 2019 Inducement Equity Plan the Plan. 